Treating neurodegeneration and neuronal injuries through the development of novel therapeutics that can prevent neuronal cell death

In the Press

Magnolia Neurosciences Corporation Announces that its Subsidiary Receives $20 Million CPRIT Grant to Develop Novel Therapies to Treat Chemotherapy-Induced Neurological Conditions

Click Here

New Houston Biotech Magnolia Tejas Plans Trials with $20M CPRIT Grant


Accelerator Life Science Partners Launches Magnolia Neurosciences Corporation with $31 Million Series A to Develop Targeted Neuroprotective Therapies

Click Here

Manhattan biotech startup to commercialize MD Anderson research

Crain’s NY

Developing Neuroprotective Therapies: Defending the Nervous System from Damage

Technology Networks

New Biotech Magnolia Neurosciences Gets $31M For Neuroprotective Drugs